Blinklab Limited · ASX:BB1
Blinklab — AusBioInvest, JMM Sydney Investor Lunch and BioFuture NYC 2024
23 slides from Blinklab's conference presentation, Oct 29, 2024
Slide 1: BlinkLab presents at AusBioInvest, JMM Sydney Investor Lunch, and BioFuture in NYC
29 October 2024 BlinkLab presents this week at AusBioInvest, JMM Sydney Investor Lunch, and BioFuture in NYC BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered sensory assessments to aid in the diagnosis of neurod
Slide 2: About BlinkLab Limited
About BlinkLab Limited BlinkLab, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for Autism, ADHD, Schizophrenia and other neurodevelopmental conditions. Our most advanced product is an Autism diagno
Slide 3: Early and accurate diagnosis of autism and ADHD
For personal use only Early and accurate diagnosis of autism and ADHD ASX:BB1, BlinkLab Ltd, Sydney 126 Phillip Street Level 5, NSW 2000, Dr. Henk-Jan Boele CEO Introducing a breakthrough AI-powered smartphone platform for neurological testing ASX:BB1, BlinkLab Ltd, Level 4, 216 St Georges Terrace,
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background For personal use only information about BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be al
Slide 5: What is autism?
What is autism? For personal use only ● Neurodevelopmental conditional that affects how the brain processes sensory information. ● Autism impacts: ○ Social development ○ Language development ○ Sensory processing ○ Behavior and interests
Slide 6: Autism is a $700B market in 2024 in the US alone
Autism is a $700B market in 2024 in the US alone ”The economic burden is significant and alarming” 1 For personal use only • Autism prevalence has grown to 2-4% among children2 • Autism healthcare expenses are soaring3 Costs for an autism diagnostic evaluation: $1,000 to $5,000 Costs of care are aro
Slide 7: Autism diagnosis is expensive, inaccurate, and often late
Autism diagnosis is expensive, inaccurate, and often late For personal use only Parental Autism Autism Diagnosis at Late observations screening diagnostic evaluation age 5-6 intervention Concerns arise By primary care Formal diagnosis requires input from Family Yielding poor about child’s physician,
Slide 8: BlinkLab's digital solution accelerates path to diagnosis
BlinkLab’s digital solution accelerates path to diagnosis For personal use only Parental BlinkLab Diagnostic Diagnosis at Early and personalized intervention observations screening evaluation age 2-3 and accurate monitoring Concerns arise Using our Using biomarkers. Initial diagnosis Intervention st
Slide 9: Our patented technology: neuroscience on a smartphone
Our patented technology: neuroscience on a smartphone Minuscule facial reflexes, evoked by our app, For personal use only generate a digital biomarker for autism. Evokes facial reflexes By presenting visual and auditory stimuli during smartphone use. Computer vision Facial features are tracked on th
Slide 10: Breakthrough data from large scale study on diagnostic accuracy of BlinkLab
Breakthrough data from large scale study on diagnostic accuracy of BlinkLab For personal use only Scores based on BlinkLab testing only. No additional questionnaires, such as ADOS of M-CHAT. Paper submitted for publication
Slide 11: Our AI technology detects autism and ADHD
Our AI technology detects autism and ADHD For personal use only BlinkLab precisely measures sensory sensitivity in people with autism and ADHD.
Slide 12: BlinkLab App and Online Portal are fully developed
BlinkLab App and Online Portal are fully developed Validated in >8,000 subjects tested globally, including people with limited access to healthcare. For personal use only ● Remote testing Enables accessible and global diagnostics. ● Scalable solution Easily adaptable for clinical and diverse researc
Slide 13: BlinkLab is collaborating with world-leading institutions
BlinkLab is collaborating with world-leading institutions Since our product launched in 2022, we have established global partnerships academic and clinical institutes. 2022 2023 2024 ongoing For personal use only Proof-of-concept of smartphone-based Princeton University neurometric evaluations. Mult
Slide 14: BlinkLab outperforms FDA-approved digital peers
BlinkLab outperforms FDA-approved digital peers We are leaders in the rapidly growing space of digital diagnostics and therapeutics. For personal use only Sensitivity 85% 52% 71% Specificity 84% 19% 81% Smartphone-based Yes Yes No FDA approval No - 510(k) Yes - De Novo Yes - 510(k)
Slide 15: First product to monitor the effect of therapy in real-time
First product to monitor the effect of therapy in real-time For personal use only Real-time drug monitoring offers a path to even larger recurring revenues via subscription-based models.
Slide 16: We are experts in science, tech and commercialization
We are experts in science, tech and commercialization For personal use only Henk-Jan Boele, CEO Anton Uvarov, COO Bas Koekkoek, CSO Peter Boele, CTO Executive director MD, PhD, Entrepreneur and MBA, PhD, Biotechnology Analyst PhD, Assistant Professor of MA, PhD candidate, Erasmus MC neuroscientist a
Slide 17: We are backed up by an expert advisory board
We are backed up by an expert advisory board For personal use only Company Chairman Company Director Company Director Scientific advisor Scientific advisor Scientific advisor Brian Leedman Jane Morgan Richard Hopkins Prof. Samuel Wang Prof. Chris De Zeeuw Prof. Javier Medina Experienced Chairman and
Slide 18: Optimizing AI and machine learning for BlinkLab Dx
Optimizing AI and machine learning for BlinkLab Dx Establishing academic partnerships is crucial not only for academic and clinical adoption but also for training our ML and AI models with diverse datasets that reflect real-world diagnoses. For personal use only PREVIOUS STUDIES CURRENT WORK Our bin
Slide 19: R&D Pipeline
R&D Pipeline Our R&D pipeline is focused on obtaining FDA 510(k) clearance and EU regulatory approval for BlinkLab as a diagnostic adjunct for autism and ADHD. For personal use only Pre-clinical development Early clinical development Feasibility clinical studies Pivotal clinical studies Regulatory a
Slide 20: Important milestones
Important milestones News pipeline: Updates on regulatory studies on autism and ADHD and new partnerships For personal use only Milestone Timeframe Start of activities for FDA registrational study in autism *2Q 2024 Interim data from ADHD clinical study in EU *3Q 2024 Appointment of US based CRO to
Slide 21: Capital structure of ASX:BB1
Capital structure of ASX:BB1 For personal use only Pre-IPO Overview (November 2021 – March 2024) November 2021: Seed Raising of A$1.2M A$0.07 November 2023: Pre-IPO Raising of A$1.4M A$0.12 April 2024: IPO Raising of A$7.0M A$0.20 Public Market Overview (28 October 2024) Share Price A$0.26 Shares on
Slide 22: Intellectual property
Intellectual property Our patents prohibit other parties to conduct neurometric testing using mobile devices. For personal use only BlinkLab has consistently prioritized the development We are represented by the US-based law firm, Meagher Our portfolio comprises patents filed both by Princeton and p
Slide 23: For further information please contact
ASX:BB1 For personal use only For further information please contact: Henk-Jan Boele (MD, PhD) Brian Leedman Chief Executive Officer Non-Executive Chairman henkjan@blinklab.org brian@blinklab.org M: +31 (0) 611 132 247 M +61 (0) 412 281 780 www.blinklab.org | info@blinklab.org | BLINKLAB LIMITED | A
BlinkLab — AusBioInvest, JMM Sydney Investor Lunch and BioFuture NYC 2024 on 6ix